
Fostering innovation from business models to DeepTech
The journey so far
If we look at our startup ecosystem journey so far, it has flourished largely on the back of business model innovation. From food delivery apps and e-commerce to fintech and gig economy platforms, startups have created new value by reimagining how services are delivered. While this has driven revenue and encouraged entrepreneurship, it's time to aim higher. As Mr. Goyal emphasised, the next frontier is DeepTech — technology grounded in scientific discovery, engineering excellence, and fundamental research.
But what is DeepTech? One will get different answers depending on who you ask. Ask around in VC circles or among founders, and the usual buzzwords emerge — AI, robotics, Internet of Things (IoT), drones etc. While these are important, DeepTech is far broader.
Material science, power electronics, advanced manufacturing, and molecular drug research are the fields which underpin critical advances in everything from energy systems and robotics to next-generation healthcare and AI hardware. For example, what makes drones both lightweight and durable? Material science. Why is China ahead in battery tech? Because companies like BYD invested early in core chemistry and engineering, and not just assembly.
DeepTech isn't about repackaging existing components. It's about bold and original work. It's about building from scratch, failing repeatedly, and pushing the boundaries of what is possible.
Building DeepTech
Understanding DeepTech is like peeling an onion with each layer revealing new dependencies and challenges. There are five core pillars which must align — a product mindset; R&D culture; technical depth; the educational ecosystem; and supportive government policies.
Product mindset is a big missing link. Let's start with a simple question. Which globally recognised product, across sectors — consumer, industrial, medical, telecom, mobility etc — have been conceived and built in India? Even in software, our supposed strength, we haven't produced tools like TensorFlow, Android, QNX, or SAP. While Indian talent leads some of the world's top companies, the DNA of product creation remains weak at home. China began by reverse engineering global products, steadily moving up the value chain, and eventually creating new products with original R&D.
A product mindset and R&D go hand in hand.
Without a culture of experimentation and long-term thinking, no amount of funding can build DeepTech. For R&D culture to flourish, founders need to dirty their hands in technicality. Great DeepTech companies are built by founders with hands-on technical expertise. Think of Google, Tesla, NVIDIA, and Microsoft. Their founders were engineers, builders, and coders. Larry Page and Sergey Brin wrote the algorithm that became Google while Bill Gates wrote software as a teenager.
To create such companies from scratch, we need founders with deep domain knowledge and an urge to solve complex problems, and not just manage teams.
Moreover, to promote technical depth, our education system needs to change its focus from tools to fundamentals. The journey towards DeepTech starts in the classroom. But how many Indian colleges teach AI or robotics from first principles, the mathematical derivation of AI or close loop control systems fundamentals? Beyond a few IITs, most focus on tool-based training, not foundational understanding. As a result, our engineers often become tool users, not tool creators.
We can emulate the likes of MIT and Stanford, where students master core theory before picking up tools. Multidisciplinary collaboration is another must. Most innovations especially in healthcare, mobility, or automation lie at the intersection of fields. Our college projects should involve multi-disciplinary student participation. We must move toward academia-industry collaboration, internships, and real-world problem-solving. In the U.S., the Defense Advanced Research Projects Agency has funded challenges that have fostered innovation in robotics, leading to breakthroughs like Intuitive Surgical's Da Vinci robot.
And finally, smarter government support will always be a catalyst. India has institutions like the National Research Development Corporation (NRDC) to promote R&D, but many of the qualifying criteria are irrational. For example, why restrict funding to startups only inside incubators? Shouldn't we evaluate based on the technical depth of the founders, the R&D roadmap, and its potential impact?
DeepTech startups often need access to fabrication labs, pilot facilities, and test and certification centres, all of which are costly infrastructure the startups themselves can't build. Micro, Small and Medium Enterprises often lack precision, and large corporations demand volumes that early-stage ventures can't deliver.
The government must create shared facilities, and affordable, high-quality spaces for low-volume, high-precision prototyping and testing. This is the only way to bridge the gap between idea and viable product.
The road ahead
India's aspiration to lead in DeepTech is both timely and necessary. But to realise this vision, we must orchestrate a coordinated shift across the entire ecosystem.
Founders must deepen technical expertise and adopt a true product plus R&D mindset. Educational institutions must prioritise fundamentals and interdisciplinary learning, and the government must offer smarter, broader, and more agile support.
Only through this kind of systemic transformation can we build world-class DeepTech products which are driven by science, born in India, and built for the world.
Bhupendra Bhate is CEO and co-founder of Saintiant Technologies Pvt Ltd, a company specialising in advanced medical devices powered by AI.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fibre2Fashion
28 minutes ago
- Fibre2Fashion
Global trade deterioration eases in Jun: S&P Global PMI data
Global trade conditions continued to deteriorate at the end of the second quarter (Q2) this year and the rate of decline eased for a second successive month and was only marginal, worldwide purchasing managers' index (PMI) surveys compiled by S&P Global Market Intelligence indicate. The seasonally-adjusted global PMI new export orders index, sponsored by JPMorgan, rose to 49.1 in June, up from 48 in May. Posting below the 50 neutral mark for a third successive month, the latest data indicated another contraction in trade activity. While the global manufacturing sector's export contraction persisted in June, the rate of decline softened to the slowest in the current three-month sequence, Jingyi Pan, economics associate director of operations-IMPG at S&P Global Market Intelligence, wrote on the company's website. Global trade conditions continued to deteriorate at the end Q2 2025 and the drop rate eased for a second month in a row and was only marginal, S&P Global Market Intelligence said. The number of top ten trading economies reporting higher goods exports was just two at the end of Q2: India and the US. India continued to lead export growth by a wide margin with a further acceleration in the growth rate. Further front-loading of goods orders ahead of the higher US tariffs deadline (July 9) supported the slower pace of deterioration in goods trade. This was evident with global production growth resuming at the quickest pace since February as manufacturers worked through existing orders in the lead up to the anticipated deadline. Additionally, stock building was again elevated among US manufacturers, though subdued across the rest of the world. Sentiment data also pointed to muted optimism regarding growth in the year ahead. Business confidence stayed below the series average reflecting some apprehension regarding the outlook, especially surrounding trade. Mentions of 'uncertainty' among goods producers were also elevated at multiples of the historical average, albeit down further from the peak in April. Even if trade uncertainty should ease in the coming months - the hangover from front-loading of goods orders in the first half of 2025 may lead to more subdued trade conditions in the coming months, Pan observed. The contraction in export business was broad-based in June, with the rates of reduction softening across both developed and emerging markets. After recording a steeper rate of export contraction for the first time in three years, emerging markets export business declined marginally at the end of the second quarter, he added. The number of top ten trading economies reporting higher goods exports remained at just two at the end of Q2 2025: India and the United States. India continued to lead export growth by a wide margin with a further acceleration in the rate of expansion. Demand strengthened from across the globe, especially from the United States. This led to Indian manufacturing exports rising at the third-fastest pace since data collection began for the series in March 2005. Goods export orders growth also accelerated in the United States to the quickest pace in just over a year despite trade policy impact. Modest slowdown in goods trade activity was recorded in Japan and South Korea, while only marginal declines were reported in the European Union and China. Fibre2Fashion News Desk (DS)


Time of India
41 minutes ago
- Time of India
US senators warn Nvidia CEO about upcoming China trip
Academy Empower your mind, elevate your skills A bipartisan pair of U.S. senators sent a letter to Nvidia CEO Jensen Huang on Friday about an upcoming trip to China, warning the CEO to refrain from meeting with companies that are suspected of undermining U.S. chip export controls The letter from Republican Senator Jim Banks and Democratic Senator Elizabeth Warren asked Huang to also abstain from meeting with representatives of companies that are working with the People's Republic of China's military or intelligence bodies. The senators also asked Huang to refrain from meeting with entities named on the U.S. restricted export list."We are worried that your trip to the PRC could legitimize companies that cooperate closely with the Chinese military or involve discussing exploitable gaps in U.S. export controls," the senators wrote. Huang planned to visit China on Nvidia spokesperson said, "American wins" when its technology sets "the global standard," and that China has one of the largest bodies of software developers in the world. AI software "should run best on the U.S. technology stack, encouraging nations worldwide to choose America," the spokesperson said. In May at the Computex trade show in Taipei, Huang praised President Donald Trump's decision to scrap some artificial intelligence chip export controls and described the prior diffusion rules as a failure.U.S. restrictions in April on AI chips Nvidia modified to comply with export controls to China would reduce Nvidia's revenue by $15 billion, the CEO hardware necessary to power advanced AI is now subject to a bipartisan consensus related to the free export of such hardware, the senators wrote. Advanced AI hardware could "accelerate the PRC's effort to modernize its military," the letter reads. U.S. lawmakers have grown increasingly concerned about efforts to circumvent export controls to China and proposed a law that would force AI chip companies to verify the location of their products. Last month, Reuters reported that a senior U.S. official said the AI firm DeepSeek is aiding China's military and intelligence operations, and sought to use shell companies to circumvent U.S. AI chip export controls to China. Nvidia is planning to launch a cheaper version of its flagship Blackwell AI chips for China, Reuters reported in senators said in the letter they had previously expressed concern that Nvidia's actions could support the AI and chip industries in China and cited Nvidia's new research facility in Shanghai as an example.


News18
an hour ago
- News18
'Pulp Fiction? Not Quite': How Indian Oranges Are Powering A French Medicine To Treat Varicose Veins
'We are proud that the oranges grown in Indian soil are now an integral part of a medicine used by millions across the world," Aurelien Breton, managing director, Servier India, told News18. 'We procure oranges from Maharashtra, Telangana, Andhra Pradesh, MP, and Rajasthan currently." According to IQVIA data, Daflon's 500mg and 1000mg stand at a value of Rs 61 crore as per moving annual turnover, May 2025, ranking 2nd in the varicose therapy market. The average number of patients treated in a month is 1.2 lakhs. The citrus supply chain The Indian-sourced oranges are first processed locally—cleaned, dried, and converted into powder form. This citrus powder is then exported to Servier's manufacturing headquarters in France, where it undergoes sophisticated processing to extract the active pharmaceutical ingredients (APIs). Interestingly, those APIs are then re-imported back to India, where the final formulation of Daflon is completed for domestic distribution. This circular, transcontinental journey of a single orange—from a farm in Nagpur to a lab in northern France and back to a pharmacy shelf in Delhi—highlights the globalisation of pharmaceutical supply chains and India's growing importance as a trusted sourcing and manufacturing hub. The move wasn't just about logistics or cost-efficiency. According to Breton, Indian oranges matched the quality standards required for flavonoid extraction. 'We achieved 100% reliance on local Indian oranges through our Indian supply chain with effect from the financial year 2021." Indian oranges matched the former Spanish and Mexican counterparts. '2000 metric tons of small oranges were procured in the financial year 2023-24. We work with aggregators and farmers in multiple states in India," said Breton. Company set to bring precision cancer medicine Servier Pharma is set to bring precision cancer treatments to India. 'Unlike traditional chemotherapy, these therapies act on specific genetic mutations that are responsible for causing the cancer," Breton said. Out of three novel drugs coming into the Indian market, the first drug, Ivosidenib, targets a mutated protein known as isocitrate dehydrogenase 1 (IDH1), which is found in a subset of patients with cholangiocarcinoma (a type of biliary tract cancer) and acute myeloid leukemia (a form of blood cancer). 'Epidemiological data show a high prevalence of biliary tract cancers along the Ganga River basin, supporting the need for this targeted option, which can significantly delay disease progression. In clinical trials, Ivosidenib has demonstrated more than a threefold improvement in survival for AML (blood cancer) patients." The drug was officially launched in India in June 2025.